Please assess the completion status of the following clinical trial:

Trial Title: Low-dose Decitabine for the Treatment of Decreased Donor Chimerism After Allogeneic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* all patients after allogeneic stem cell transplantation~* decreasing of donor chimerism to less than 97%~* providing inform consent~Exclusion Criteria:~* patients with documented relapse disease~* patients with documented positive MRD+ (\>0.1% via flowcytometry or PCR)~* patients with active infection or grade III-IV GVHD

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): The peripheral and bone marrow T cell and mono nucleated cell chimerism will be closely followed-up. In case of decreasing donor chimerism, patients will receive low-dose decitabine with 5mg/m2 daily for 5 days every 6-8 weeks until the chimerism recovered to full donor type (\>98%).

Based on this trial design, predict the completion outcome and termination type (if applicable).